Search clinical trials for: split-virion, non-adjuvanted H1N1 vaccine of 15 μg

Total 132 results

Jiangsu Province Centers for Disease Control and...
Hualan Biological Bacterin Co. Ltd.

Completed

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older

Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza | Orthomyxoviridae Infections

China
Shanghai Institute Of Biological Products

Completed

The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine

Influenza

China
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial With Influenza A/H1N1 Vaccines

Influenza

China
Shanghai Institute Of Biological Products

Completed

Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants

Influenza

China
Jiangsu Province Centers for Disease Control and...

Completed

Safety of H1N1 Influenza Vaccination in Pregnant Women

Virus Diseases | Respiratory Tract Infections | Influenza | Orthomyxoviridae Infections

China
Shanghai Public Health Clinical Center
Beijing Ditan Hospital; National Institute for the Control of Pharmaceutical...

Unknown

Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients

Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza | Orthomyxoviridae Infections

China
Chinese Academy of Sciences
Jiangsu Province Centers for Disease Control and Prevention; Hualan Biological...

Unknown

Immunogenicity Study of S-OIV H1N1 Influenza Vaccine

Human Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Influenza | Swine-origin A/H1N1 Influenza

Finland
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
Green Cross Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Influenza Infection
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Orthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus Infection

Belgium
GlaxoSmithKline

Completed

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Influenza | Influenza Vaccines

Taiwan, Hong Kong, Thailand, Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

Influenza | Orthomyxoviridae Infections | Influenza A Virus Infection

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines

Influenza

China
Hualan Biological Engineering, Inc.

Completed

Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation)

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

France
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults

Influenza | Swine-origin A/H1N1 Influenza

France
University of Oxford

Completed

Swine Flu (Novel Influenza A H1N1) Vaccine Study

Influenza

United Kingdom
National Institute of Allergy and Infectious Diseases...
Emory University

Completed

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

United States
Instituto Nacional de Salud Publica, Mexico
Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.

Withdrawn

Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1

Influenza

Mexico
Chiltern Pesquisa Clinica Ltda

Completed

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

H1N1 Influenza Virus | Invasive Solid Tumors

Brazil
French National Agency for Research on AIDS and...
GlaxoSmithKline

Completed

Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)

HIV Infections

France
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children

Influenza | Orthomyxoviridae Infections | Orthomyxovirus Infections

Finland
Ology Bioservices

Completed

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

Influenza

Austria, Belgium, Finland, Germany, Latvia, Lithuania, Netherlands
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children

Influenza

China
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines

Influenza | Myxovirus Infection | Orthomyxovirus Infections

France
Ology Bioservices

Completed

Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents

Influenza, Avian

Australia, Finland, Singapore, Spain
Butantan Institute
Fundação Butantan

Recruiting

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Influenza, Human

Brazil
Ology Bioservices

Completed

H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older

Influenza

Japan
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea

Influenza

Korea, Republic of
Institut National de la Santé Et de la Recherche...
MCM Vaccines B.V.

Completed

Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients (Transfluvac)

Immunosuppression | Renal Transplant Recipients

France
Sinovac Biotech Co., Ltd
Ministry of Science and Technology of the People´s Republic of China

Completed

Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects

Influenza

China
Ology Bioservices

Completed

Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)

Influenza

Austria
GlaxoSmithKline

Completed

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

Respiratory Syncytial Virus Infections

Finland, Spain, Canada, United States, Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India

Influenza | Pandemic Influenza | Influenza A Virus, H1N1 Subtype

India
Institut National de la Santé Et de la Recherche...
MCM Vaccines B.V.

Completed

Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women (PREFLUVAC)

Influenza

France
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation

Influenza | Orthomyxoviridae Infections

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)

Influenza

France
Dalhousie University
Mount Sinai Hospital, Canada; IWK Health Centre; MCM Vaccines B.V.

Completed

Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine

Influenza

Canada
Enimmune Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old

Enterovirus Infections

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)

Influenza

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Spain, France, Lithuania, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Influenza

United States
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Czech Republic, Lithuania, Belgium

3

Subscribe